4SC-202
Overview[edit | edit source]
4SC-202 is an investigational drug that is being studied for its potential use in the treatment of various types of cancer. It is a small molecule inhibitor that targets specific enzymes involved in the regulation of gene expression. The drug is currently undergoing clinical trials to evaluate its efficacy and safety in cancer patients.
Mechanism of Action[edit | edit source]
4SC-202 is classified as a histone deacetylase (HDAC) inhibitor. HDACs are enzymes that remove acetyl groups from histone proteins, leading to a closed chromatin structure and suppression of gene transcription. By inhibiting HDACs, 4SC-202 promotes an open chromatin structure, thereby enhancing the transcription of genes that can induce cell cycle arrest, differentiation, and apoptosis in cancer cells.
Clinical Development[edit | edit source]
4SC-202 is being developed by 4SC AG, a German biotechnology company. The drug has shown promising results in preclinical studies, demonstrating the ability to inhibit tumor growth in various cancer models. It is currently being evaluated in early-phase clinical trials for its safety, tolerability, and preliminary efficacy in patients with advanced solid tumors and hematological malignancies.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of 4SC-202 is characterized by its absorption, distribution, metabolism, and excretion properties. The drug is administered orally and has been shown to have a favorable bioavailability. It is metabolized primarily in the liver and excreted through the kidneys. The half-life of 4SC-202 allows for once-daily dosing in clinical settings.
Side Effects[edit | edit source]
As with many investigational drugs, 4SC-202 may cause side effects. Commonly reported adverse effects include fatigue, nausea, vomiting, and hematological abnormalities such as thrombocytopenia and neutropenia. The safety profile of 4SC-202 is still being established through ongoing clinical trials.
Potential Indications[edit | edit source]
4SC-202 is being investigated for its potential use in treating a variety of cancers, including but not limited to:
Research and Future Directions[edit | edit source]
Ongoing research is focused on understanding the full therapeutic potential of 4SC-202, including its use in combination with other anticancer agents. Studies are also exploring biomarkers that may predict response to treatment, which could help in personalizing therapy for patients.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
